Balanced product information
Evidence, limitations and safety — in one consistent format.
This page separates authorised uses from investigational or reported uses. It does not provide personal medical advice or dosing instructions.
Product name
Nicotinamide adenine dinucleotide (NAD+) with nicotinamide mononucleotide (NMN)
Catalogue label details describe what is displayed; they do not independently verify composition, quality, batch release or UK marketing authorisation.
What is it?
NAD+ is a coenzyme present in cells and involved in energy transfer, redox reactions and signalling. NMN is a naturally occurring precursor used by the body to make NAD+.
A 600mg NAD+ plus 400mg NMN injection pen is not the same as normal dietary exposure, oral supplements or material used in a controlled study.
Intended / recognised uses
Authorised / recognised uses
- No UK-authorised medical use has been established for this injectable NAD+/NMN combination.
Reported / investigational uses
- NAD precursors are being studied in ageing, metabolism and selected diseases, and intravenous NAD+ is marketed by some clinics for wellness.
- Systematic reviews have not established robust clinical outcome benefits for injectable NAD+ used for anti-ageing or wellness, and evidence cannot be transferred to this pen.
How it works
NAD+ participates in cellular energy reactions and is used by enzymes involved in DNA repair and cell signalling. NMN can enter NAD-biosynthesis pathways.
Changing a blood or tissue biomarker does not by itself prove improved energy, cognition, longevity or disease outcomes.
Potential benefits / effects
- Small studies of NAD precursors have explored metabolic and biochemical outcomes, but findings are inconsistent and often relate to oral products.
- No reliable clinical benefit has been established for this exact injectable combination, concentration or delivery system.
Potential benefit is not a guarantee of benefit for any individual.
Risks & warnings
- Human safety data for repeated subcutaneous delivery of this exact combination are inadequate.
- Injection introduces risks of contamination, infection, tissue injury, allergy and incorrect concentration.
- Long-term effects of altering NAD-related pathways, including in people with cancer or complex metabolic disease, remain uncertain.
Possible side effects
Frequency not established
- There are no dependable common-side-effect rates for this product.
- Local pain, redness or swelling, headache, nausea, dizziness, flushing or chest discomfort have been reported in some NAD-related treatment settings, but routes and formulations differ.
Serious or urgent concerns
- Breathing difficulty, facial swelling, severe chest symptoms, fainting, high fever or a spreading injection-site reaction needs urgent assessment.
- Unknown long-term adverse effects remain possible.
Who should not use it / precautions
- It should not be used outside a properly authorised research or specialist setting.
- Pregnancy, breastfeeding, childhood, active cancer, serious liver or kidney disease, significant cardiovascular disease and immune disorders require particular caution.
- A health claim based on cellular biology is not evidence of individual suitability.
Interactions
- Reliable interaction studies for injectable NAD+/NMN are lacking.
- Interactions with cancer therapies, metabolic medicines or supplements that affect related pathways are unknown rather than absent.
- A clinician or pharmacist should review all medicines and supplements before any investigational exposure.
Regulatory / legal status
- The combined injectable product shown has no verified UK marketing authorisation.
- It should not be described as an approved anti-ageing, energy, cognitive or longevity medicine.
Monitoring / professional supervision
- There is no validated monitoring programme that makes unsupervised use safe.
- A legitimate study would define eligibility, product quality, laboratory measures, adverse-event surveillance and stopping criteria.
- Routine wellness tests cannot establish the identity or safety of an unverified injectable product.
Evidence & sources
Sources are selected for regulatory status, recognised uses and material safety information. They do not validate the HELIX-labelled presentation.
- PubMed — Systematic review of NAD+ and precursor supplementation
- PubMed — Systematic review of NMN human studies
- ClinicalTrials.gov — Intravenous NAD+ study NCT06382688
- MHRA — Yellow Card adverse-event reporting
Sources accessed and content reviewed 12 September 2026. Regulatory status can change; consult the current official record.
Information disclaimer
HELIX — FOR INFORMATION ONLY. NOT FOR SALE.
The products displayed on this website are presented strictly for informational and educational purposes, helping visitors understand their descriptions, features and specifications. No products are offered for sale through this website, and no product orders or payments are accepted through this platform.
The information on this website does not constitute medical advice, a prescription or a recommendation to use any product. Displaying a product does not establish its regulatory approval, safety or suitability for an individual. Please consult an appropriately qualified healthcare professional for personal medical advice.
For a UK-facing website, this disclaimer does not by itself establish legal compliance. Public advertising of prescription-only medicines and advertising of unlicensed medicines are subject to legal restrictions; the catalogue, wording and presentation require appropriate regulatory review.
Licensed-provider information
Where permitted by applicable law, HELIX may display contact details for independent third-party providers whose registration details have been checked against an appropriate official register. Visitors may contact a listed provider directly to enquire about lawful availability and eligibility requirements.
Any supply is subject to the provider’s assessment, applicable regulations, and verification of all required documentation, which may include a valid prescription, professional licence, identification or other authorisation. A referral does not guarantee availability, eligibility or supply.
Registration status can change. Review the provider's regulator, registration number, official-register record and last-checked date, then verify the current status independently before engaging.